MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models.

Vena, Francesca; Jia, Ruochen; Esfandiari, Arman; Garcia-Gomez, Juan J; Rodriguez-Justo, Manuel; Ma, Jianguo; Syed, Sakeena; Crowley, Lindsey; Elenbaas, Brian; Goodstal, Samantha; Hartley, John A; Hochhauser, Daniel.

Afiliação

Vena F; Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O'Gorman Building, University College London, London WC1E 6DD, UK.
Jia R; Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O'Gorman Building, University College London, London WC1E 6DD, UK.
Esfandiari A; Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O'Gorman Building, University College London, London WC1E 6DD, UK.
Garcia-Gomez JJ; Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O'Gorman Building, University College London, London WC1E 6DD, UK.
Rodriguez-Justo M; Department of Research Pathology, UCL Cancer Institute, London EC1M6BQ, UK.
Ma J; EMD Serono Research and Development Institute, Billerica 01821, MA, USA.
Syed S; EMD Serono Research and Development Institute, Billerica 01821, MA, USA.
Crowley L; EMD Serono Research and Development Institute, Billerica 01821, MA, USA.
Elenbaas B; EMD Serono Research and Development Institute, Billerica 01821, MA, USA.
Goodstal S; EMD Serono Research and Development Institute, Billerica 01821, MA, USA.
Hartley JA; Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O'Gorman Building, University College London, London WC1E 6DD, UK.
Hochhauser D; Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, Paul O'Gorman Building, University College London, London WC1E 6DD, UK.